Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 19, 2025
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.com5.07
+0.06 (+1.2%)
NASDAQ:DRTSW (12/19/2025, 8:00:01 PM)
0.335
+0.01 (+1.52%)
Find more stocks in the Stock Screener
DRTS Latest News and Analysis
